| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ee63f1a7e834f9bf7485546ea28415f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N43-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0017 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 |
| filingDate |
2013-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d4f0bc04cab9a0a1cc9f4486ecb1388 |
| publicationDate |
2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2660357-C2 |
| titleOfInvention |
Transdermal parasiticidal formulations |
| abstract |
FIELD: veterinary. n SUBSTANCE: group of inventions relates to the field of veterinary medicine, in particular to transdermal parasiticidal formulations and a method for treating endoparasitic or ectoparasitic invasion. Composition suitable for transdermal administration for the treatment of endoparasitic or ectoparasitic invasion comprises a therapeutically effective amount of levamisole anthelmintic agent dissolved in a solution containing isopropyl myristate and D-limonene, where isopropyl myristate and D-limonene are collectively present in an amount of 1-55% w/v of the entire composition, and the molar ratio of isopropyl myristate to D-limonene ranges from about 10:1 to about 15:1. n EFFECT: group of inventions provides a stable transdermal parasiticidal formulation by combining isopropyl myristate and D-limonene as a solvent system. n 28 cl, 11 tbl, 13 ex |
| priorityDate |
2012-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |